Jan’08 business news digest

by Alexey Bersenev on February 3, 2008 · 0 comments

in business, clinical trials and cases

I’ll review some business news monthly or every 2 months and post them like a digest.
So, my last month business news pick:

Celprogen Inc. (San-Pedro, CA, USA) became the first company launched Cancer Stem Cells lines for sell. Currently company offers 11 lines.
Just one example:

Human Pancreatic Cancer Stem Cell:
T25 plated cells shipped at room temperature $550
T75 plated cells shipped at room temperature, $750
Population doubling 120 or up to 12 passages.

read full story
————–

ARIUS Research Inc. (TSX: ARI; Toronto, Canada) completes pre-IND Meeting with FDA for lead “CD44 Cancer Stem Cell Program”.

ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate

So, anti-CD44 antibody targeting cancer stem cells on the way to clinical trial!

read company’s press release
————–

Sangamo BioSciences, Inc. (Nasdaq: SGMO; Richmond, CA, USA) announced the initiation of a randomized, single-blind, placebo-controlled, multi-center Phase 2 clinical trial of stem cell mobilizer SB-509 in subjects with diabetic neuropathy.

SB-509 is an injectable formulation of plasmid DNA that encodes a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)), designed to upregulate the vascular endothelial growth factor A (VEGF-A) gene.
Pre-clinical studies of a VEGF-activating ZFP TF demonstrated statistically significant (p<0.05) increases in stem cells in the bone marrow and bloodstream of animals compared to a placebo. These preclinical findings led to a small-scale clinical study into the effect of SB-509 administration on stem cell mobilization in human subjects with diabetic neuropathy.

read press release
————–

Aastrom Biosciences, Inc. (Nasdaq: ASTM; Ann Arbor, Michigan, USA), announced the first patient has been treated with the Company’s autologous stem cell therapy for dilated cardiomyopathy.

Company’s press release
————–

Tengion, Inc. (East Norriton, PA, USA) launched third Phase 2 multi-center clinical trial of its Neo-Bladder Augment derived from a patient’s own (autologous) cells.

Company’s press release

Read more:Tengion Pioneers Autologous Tissue Engineered Regenerative Medicine Products
————–

Lonza Group AG (Basel, Switzerland) offers a new cell type called “Poietics” Human Natural Killer Cells for immunology research.

Peripheral Blood NK Cells (negative selection) 5 million cells/amp, cryopreserved = 699.00 USD
Guaranteed with >5 million viable cells per cryopreserved ampoule after thawing

learn more about product
————–

Invitrogen (Nasdaq: IVGN; Carlsbad, CA, USA) announces acquisition of CellzDirect

Invitrogen purchased privately-held CellzDirect, Inc., based in Research Triangle Park, North Carolina, in a cash transaction for approximately $57 million.
CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs.

press release
————–
Girl dies in stem cell trial for Batten’s disease.

StemCells, Inc. (Nasdaq: STEM; Palo Alto, CA, USA) StemCells, Inc. (NASDAQ: STEM) provided an update on the Company’s Phase I clinical trial of its proprietary HuCNS-SC ® product candidate.

The patient, a nine-year-old girl, was transplanted with HuCNS-SC cells in January 2007 and was due to return this month to the trial site, Oregon Health & Science University ’s (OHSU) Doernbecher Children’s Hospital, for her 12 month follow-up.
Based upon the facts and information available at this time, it is the opinion of the principal investigators at OHSU, the independent Data Safety Monitoring Committee, and the Company’s medical experts that this death was most likely due to the natural progression of the disease and not related to the HuCNS-SC cells or the transplantation procedure itself. StemCells, Inc. is continuing to investigate the death and has been in contact with the U.S. Food and Drug Administration (FDA) since first becoming aware of the patient’s condition. The Company expects to provide additional updates about the trial in the future.

Company’s press release
————–

finally, the top news of the month:

Stemagen (La Jolla, CA, USA) First to Create Cloned Human Embryos from Adult Cells

Stemagen, a privately held embryonic stem cell research company, announced today it has become the first in the world to create, and meticulously document, a cloned human embryo using somatic cell nuclear transfer (SCNT).

press release

study published in Stem Cells 17 Jan, Open Access
————–

My sources:
Cell Therapy News
Biospace
Regeneration Station

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: